Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Endoscopic remission in ulcerative colitis (UC) is associated with improved clinical outcomes. We assessed whether histological remission predicts clinical outcomes, estimated the magnitude of effect, and determined whether histological remission provides additional prognostic utility beyond clinical or endoscopic remission. METHODS: Bibliographic databases were searched for studies in inflammatory bowel disease providing baseline histological status and relation to an outcome of clinical relapse or exacerbation. Our primary analysis compared the proportion of patients with study-defined histological remission vs. the proportion with histological activity who developed clinical relapse/exacerbation. Additional analyses compared the proportion with relapse/exacerbation for the presence vs. absence of different histological features and for histological remission vs. endoscopic remission and clinical remission. A fixed-effect model was used for meta-analysis, with a random-effects model if statistical heterogeneity was present. RESULTS: Fifteen studies met inclusion criteria. The major methodological shortcoming was lack of blinding of the assessor of clinical relapse/exacerbation to baseline histological status in 13 of the 15 studies. Relapse/exacerbation was less frequent with baseline histological remission vs. histological activity (relative risk (RR)=0.48, 95% confidence interval (CI) 0.39-0.60) and vs. baseline clinical and endoscopic remission (RR=0.81, 95% CI 0.70-0.94). Relapse/exacerbation was also less common in the absence vs. presence of specific histological features: neutrophils in epithelium (RR=0.32, 95% CI 0.23-0.45), neutrophils in lamina propria (RR=0.43, 95% CI 0.32-0.59), crypt abscesses (RR=0.38, 95% CI 0.27-0.54), eosinophils in the lamina propria (RR=0.43, 95% CI 0.21-0.91), and chronic inflammatory cell infiltrate (RR=0.28, 95% CI 0.10-0.75). Histological remission was present in 964 (71%) of the 1360 patients with combined endoscopic and clinical remission at baseline. CONCLUSIONS: UC patients with histological remission have a significant 52% RR reduction in clinical relapse/exacerbation compared with those with histological activity. Histological remission is also superior to endoscopic and clinical remission in predicting clinical outcomes. As ~30% of patients with endoscopic and clinical remission still have histological activity, addition of histological status as an end point in clinical trials or practice has the potential to improve clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Converging goals of treatment of inflammatory bowel disease from clinical trials and practice
Levesque, B. G., Sandborn, W. J., Ruel, J., Feagan, B. G., Sands, B. E., & Colombel, J.-F. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.08.003 · Cited by 217
Cited by
Ulcerative colitis: Recent advances in the understanding of disease pathogenesis
Porter, R. J., Kalla, R., & Ho, G.-T. (2020) · F1000Research · doi:10.12688/f1000research.20805.1 · Cited by 300
Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression?
Villablanca, E. J., Selin, K., & Hedin, C. R. H. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00604-y · Cited by 256
Eosinophils in Autoimmune Diseases
Diny, N. L., Rose, N. R., & Čiháková, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00484 · Cited by 172
Gupta, A., Yu, A., Peyrin-Biroulet, L., & Ananthakrishnan, A. N. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.09.046 · Cited by 147
Gui, X., Bazarova, A., del Amor, R., Vieth, M., de Hertogh, G., Villanacci, V., Zardo, D., Parigi, T. L., Røyset, E. S., Shivaji, U. N., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-326376 · Cited by 136
Rath, T., Atreya, R., Bodenschatz, J., Uter, W., Geppert, C. E., Vitali, F., Fischer, S., Waldner, M. J., Colombel, J.-F., Hartmann, A., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2022.10.014 · Cited by 133
Ma, C., Sedano, R., Almradi, A., Vande Casteele, N., Parker, C. E., Guizzetti, L., Schaeffer, D. F., Riddell, R. H., Pai, R. K., Battat, R., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.02.035 · Cited by 105
Maeda, Y., Kudo, S.-E., Ogata, N., Misawa, M., Iacucci, M., Homma, M., Nemoto, T., Takishima, K., Mochida, K., Miyachi, H., et al. (2022) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2021.10.019 · Cited by 68
Metadata
- Authors
- Park, S., Abdi, T., Gentry, M., & Laine, L.
- Venue
- American Journal of Gastroenterology
- Published
- 2016-12
- Volume
- 111
- Issue
- 12
- Pages
- 1692-1701
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2531437823
- Cited by
- 216
- References
- 1
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.